Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer
2017 · Journal of Clinical Oncology · 197 citations
https://doi.org/10.1200/jco.2015.66.3468